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eMost clinicians are aware that a national coverage de-
termination (NCD) for carotid angioplasty and stenting
(CAS) exists that restricts reimbursement for CAS in Medi-
care beneficiaries to patients with high-grade symptomatic
carotid stenosis who are at high risk for carotid endarterec-
tomy (CEA). Coverage is also in place for patients being
enrolled in appropriate clinical trials ofCAS.Publicationof the
Carotid Revascularization Endarterectomy Versus Stenting
Trial (CREST) in mid-2010 engendered renewed debate
about CEA vsCAS, and it was anticipated that there would be
yet another application to the Centers forMedicare andMed-
icaid Services (CMS) for reconsideration of the NCD relative
to CAS. In anticipation of same, the SVS Board of Directors
voted 21 of 22 at its June 2011meeting against any change in
the current NCD for CAS.
An application for such reconsideration was submitted,
but denied by CMS. Rather, CMS convened a Medicare
EvidenceDevelopment andCoverage Advisory Committee
(MEDCAC) meeting on January 25, 2012, to allow a
current deliberation of the state of the art technology and
science referable to carotid bifurcation atherosclerosis. The
MEDCAC differs substantially from a reconsideration of
coverage determination and, in this case, was built around
seven research questions. TheMEDCAC consists of a panel
of experts who, after reviewing the pertinent literature and
submitted commentary by interested stakeholders, and af-
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resentations, held a panel vote on the research questions.
Also germane to the timing of the MEDCAC was the
act that five different international practice guidelines were
ublished during calendar year 2011 referable to carotid
isease management. The Society for Vascular Surgery
SVS) both endorsed the multispecialty practice guidelines
ublished in January 2011 and updated its own practice
uidelines, in the September 2011 Journal of Vascular
urgery.
Given that management of carotid disease is a core
lement of vascular surgical practice, SVS had a major
resence at the MEDCAC in the form of a comprehensive
ritten document individually considering the research
uestions and constituting the bulk of the present commu-
ication. In addition, SVS executive committee members
nd delegates presented six “at-large” presentations at the
EDCAC addressing various aspects of carotid disease
anagement. MEDCAC invited speakers were chosen to
epresent a spectrum of specialties and viewpoints referable
o carotid disease (neurology, interventional cardiology,
nd vascular surgery) with such invited speakers allotted 20
inutes to present to the panel. The panel chairman repeat-
dly emphasized to all presenters and the panel that the
ssence of the meeting of the MEDCAC was a consider-
tion of the available evidence rather than individual clini-
ian experience or bias, or both.
The SVS presentations, written commentary, and in
act, the invited presentation of a vascular surgery represen-
ative (Wesley Moore, MD), were entirely consistent with
he SVS updated practice guidelines. Similar to the posture
f theMEDCAC panel, SVS practice guidelines reflect best
vailable evidence and consider the relevant clinical out-
omes to be periprocedural stroke and death.
The MEDCAC panel votes on the six research ques-
ions were concordant with SVS position statements on the
mportant elements of the natural history of high-grade
symptomatic carotid stenosis and the prediction of adverse
vents after CEA. The most striking concordance between
he SVS position and the MEDCAC panel vote related to
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July 2012200 Cambriathe treatment of symptomatic carotid stenosis, where the
panel favored CEA as the optimal treatment strategy for
such patients. In the realm of asymptomatic patients, the
research questions were parsed into consideration of pro-
cedural risk for CEA and also qualifying patients by
whether they are at high risk for stroke.
Management of asymptomatic patients is influenced
by claims that optimal medical therapy has substantially
reduced the stroke risk associated with asymptomatic
carotid stenosis; however, this contention remains un-
proven by the best available evidence, particularly in
patients with high-grade stenosis, wherein intervention
would be considered by SVS guidelines. Although mul-
tiple practice guidelines published in 2011 support the ferformance of CEA in appropriately selected asymp-
omatic patients, the MEDCAC panel had low confi-
ence about the role of any intervention vs optimal
edical therapy in patients with asymptomatic carotid
tenosis. SVS supports the position that future trials in
symptomatic patients should include an optimal medi-
al therapy arm. SVS has also identified further research
n the realm of asymptomatic carotid stenosis as its
umber 1 clinical research priority.
The further course and outcomes of the CMS MEDCAC
re not clearly defined at the moment. Obviously, it will be
repository of information (the intent of this SVS docu-
ent) should CMS choose to reopen the issue of the NCDor CAS.
